These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 9575599)

  • 1. Randomized controlled trial of antioxidants in intermittent claudication.
    Leng GC; Lee AJ; Fowkes FG; Horrobin D; Jepson RG; Lowe GD; Rumley A; Skinner ER; Mowat BF
    Vasc Med; 1997 Nov; 2(4):279-85. PubMed ID: 9575599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A long-term study of policosanol in the treatment of intermittent claudication.
    Castaño G; Más Ferreiro R; Fernández L; Gámez R; Illnait J; Fernández C
    Angiology; 2001 Feb; 52(2):115-25. PubMed ID: 11228084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication.
    Castaño G; Más R; Roca J; Fernández L; Illnait J; Fernández JC; Selman E
    Angiology; 1999 Feb; 50(2):123-30. PubMed ID: 10063942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized placebo-controlled, double-blind trial of ketanserin in treatment of intermittent claudication.
    Walden R; Bass A; Rabi I; Adar R
    J Cardiovasc Surg (Torino); 1991; 32(6):737-40. PubMed ID: 1752890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving walking ability and ankle brachial pressure indices in symptomatic peripheral vascular disease with intermittent pneumatic foot compression: a prospective controlled study with one-year follow-up.
    Delis KT; Nicolaides AN; Wolfe JH; Stansby G
    J Vasc Surg; 2000 Apr; 31(4):650-61. PubMed ID: 10753272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of atorvastatin on walking performance in peripheral arterial disease.
    Bregar U; Poredos P; Sabovic M; Jug B; Sebestjen M
    Vasa; 2009 May; 38(2):155-9. PubMed ID: 19588303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P-LAS).
    Tsuchida H; Shigematsu H; Ishimaru S; Iwai T; Akaba N; Umezu S
    Int Angiol; 2006 Sep; 25(3):287-92. PubMed ID: 16878078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and microcirculatory effects of transcutaneous CO2 therapy in intermittent claudication. Randomized double-blind clinical trial with a parallel design.
    Fabry R; Monnet P; Schmidt J; Lusson JR; Carpentier PH; Baguet JC; Dubray C
    Vasa; 2009 Aug; 38(3):213-24. PubMed ID: 19736632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of gamma-linolenic acid and eicosapentaenoic acid in peripheral arterial disease.
    Leng GC; Lee AJ; Fowkes FG; Jepson RG; Lowe GD; Skinner ER; Mowat BF
    Clin Nutr; 1998 Dec; 17(6):265-71. PubMed ID: 10205349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication.
    Shahin Y; Cockcroft JR; Chetter IC
    Br J Surg; 2013 Aug; 100(9):1154-63. PubMed ID: 23842829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study.
    ; Leizorovicz A; Becker F
    Circulation; 2008 Feb; 117(6):816-22. PubMed ID: 18212283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of exercise rehabilitation on cardiovascular risk factors in older patients with peripheral arterial occlusive disease.
    Izquierdo-Porrera AM; Gardner AW; Powell CC; Katzel LI
    J Vasc Surg; 2000 Apr; 31(4):670-7. PubMed ID: 10753274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of pain-free treadmill training on fibrinogen, haematocrit, and lipid profile in patients with claudication.
    Mika P; Wilk B; Mika A; Marchewka A; Nizankowski R
    Eur J Cardiovasc Prev Rehabil; 2011 Oct; 18(5):754-60. PubMed ID: 21450630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of supervised exercise and cilostazol on coagulation and fibrinolysis in intermittent claudication: a randomized controlled trial.
    Hobbs SD; Marshall T; Fegan C; Adam DJ; Bradbury AW
    J Vasc Surg; 2007 Jan; 45(1):65-70; discussion 70. PubMed ID: 17210383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of ticlopidine on lower limb blood flow, ankle/brachial index and symptoms in peripheral arteriosclerosis. A double-blind study. The STIMS Group in Lund. Swedish Ticlopidine Multicenter Study.
    Fagher B
    Angiology; 1994 Sep; 45(9):777-88. PubMed ID: 8092543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of the walking ability in intermittent claudication due to superficial femoral artery occlusion with supervised exercise and pneumatic foot and calf compression: a randomised controlled trial.
    Kakkos SK; Geroulakos G; Nicolaides AN
    Eur J Vasc Endovasc Surg; 2005 Aug; 30(2):164-75. PubMed ID: 15890545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ethaverine hydrochloride on the walking tolerance of patients with intermittent claudication.
    Trainor FS; Phillips RE; Michie DD; Zellner SR; Hogan L; Chubb JM
    Angiology; 1986 May; 37(5):343-51. PubMed ID: 3521401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1).
    Jaff MR; Dale RA; Creager MA; Lipicky RJ; Constant J; Campbell LA; Hiatt WR
    Circulation; 2009 Jan; 119(3):452-8. PubMed ID: 19139383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketanserin in intermittent claudication: effect on walking distance, blood pressure, and cardiovascular complications.
    Thulesius O; Lundvall J; Kroese A; Stranden E; Hallböök T; Brunes L; Gjöres JE; Akesson H; Einarsson E; Ohlin P
    J Cardiovasc Pharmacol; 1987 Jun; 9(6):728-33. PubMed ID: 2442541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.